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| INTRODUCTION
Ovarian cancer is the leading cause of death from gynecological malignancies in women. Early-stage ovarian cancer is asymptomatic, and approximately 75% of patients are already in an advanced stage of the disease when diagnosed. 1 Although recent progress in the development of anticancer drugs has led to a remarkable increase in overall survival from various malignancies, including ovarian cancer, the 5-year survival rate for patients with advanced stage ovarian cancer remains low. 2 Conventional surgery and chemotherapy-based treatment modules appear to be ineffective in reducing the mortality rate of ovarian cancer because of its recurrence frequency and resistance to chemotherapy. Gene mutations in K-Ras, p53, and/or phosphatidylinositide 3-kinase (PI3 K) are related to chemoresistance in ovarian cancers. 3 For example, K-Ras mutation is associated with cisplatin resistance in ovarian cancer. 4 However, mutaome-based chemoresistance mechanisms in ovarian cancer have not been clearly elucidated.
Chemoresistance may be characterized as intrinsic chemoresistance, which is involved in pharmacokinetics/pharmacodynamics by limiting drugs uptake, enhancing efflux, or activating detoxification of drugs, or extrinsic chemoresistance, which is associated with genetic or epigenetic alterations of crucial genes. 1 Genetic alterations are reflected in DNA sequences and include mutations, deletions, amplifications, and translocations, and can result in the development and/or the utilization of non-canonical signaling pathways that are not observed in normal cells. 1 Well-characterized signaling pathways involved in the controlling of cancer development and chemoresistance are the Ras/Raf/MEKs/ERKs/RSKs and PI3 K/Akt/mTOR signaling pathways, which are generally known to control cell proliferation and transformation, cell survival and death, and cell locomotion including that associated with cancer cell metastasis. 5 These features are closed related to cancer cell malignancy and chemoresistance, which are obtained via an accumulation of genomic mutations. 6 For example, mutations of K-Ras or Raf in the Ras/Raf/ MEKs/ERKs/RSKs signaling pathway are frequently observed in cancer cells harboring chemoresistance against paclitaxel or doxorubicin in acute lymphoblastic leukemia, melanoma, colon, gastrointestinal, and non-small-cell lung cancer, 7, 8 whereas, mutations of PI3 K in the PI3 K/Akt/mTOR signaling pathway are observed in breast cancer, head and neck squamous cell carcinoma, prostate cancer, colon cancer, and non-small-cell lung cancer and are associated with a lack of cell sensitivity to anticancer drugs. 9 Regardless, the relationships between genetic alterations and chemoresistance have not been completely described.
Recently, bioinformatic data obtained from the mutaome database of the Cancer Cell Line Encyclopedia (CCLE) provided the opportunity to investigate the relationships between chemoresistance and accumulated mutations in the cancer cells. Based on CCLE mutaome data, our research group has sought to elucidate the association of a particular mutation or signaling pathway with chemoresistance, in particular, the Ras/Raf/MEKs/ERKs/RSKs and PI3 K/Akt/mTOR signaling pathways. The data indicate that 20-80% of mutations in most tumors occur in more than one gene, and those genes often include p53, PIK3, APC, PTEN, B-Raf, Ras, and others. Magnolin is a lignan compound abundantly found in Magnolia spp.
and has been widely used as an oriental medicinal herb to treat various human diseases and conditions including empyema, nasal congestion, sinusitis, and inflammation. 13 Recently, our research group reported that that magnolin is capable of suppressing cell proliferation and transformation by impairing the G1/S cell-cycle transition and inhibiting the ERKs/RSK2 signaling pathways by direct targeting of the active pockets of ERK1 and ERK2. 13 That study also showed that magnolin inhibits anchorage-independent cell transformation induced by tumor promoters such as EGF. 13 However, the biological effects of magnolin as a cancer therapeutic agent have not been fully described.
In this study, we investigated the efficacy of magnolin as an inhibitor of the ERKs/RSK2 signaling axis in cancer cells, as well as the molecular mechanism associated with the magnolin resistance of SKOV3 ovarian cancer cells.
| MATERIALS AND METHODS

| Reagents and antibodies
Chemicals such as Tris, NaCl and sodium dodecyl sulfate (SDS) for buffer preparation were purchased from Sigma-Aldrich (St. Louis, MO).
Magnolin extracted from Shin-Yi, the dried flower buds of Magnolia 
| Xenograft athymic animal experiment
Athymic nude mice (6 weeks old) were obtained from Charles River 
| Immunohistofluorescence assay
To confirm the expression of p16 Ink4a and p27 Kip1 in xenograft tumor tissues, the paraffin-invaded tumor tissue slide was deparaffinized by incubation at 60°C for 2 h, rehydrated and unmasked by boiling with 10 mM sodium citrate buffer (pH 6.0) for 10 min. After cooling, the slide was blocked with 5% goat serum in 0.5% Triton X-100/PBS at RT Figure 1A) . 3.2 | Magnolin inhibits cell-cycle transition and colony growth in TOV-112D, but not in SKOV3
The Ras/Raf/MEKs/ERKs/RSK2 signaling pathway has an important role in cell proliferation and cancer development by stimulation of growth factors. 17 Our previous results demonstrated that inhibition of ERK1 and ERK2 by magnolin suppresses G1/S cell-cycle transition in premalignant JB6 Cl41 cells. 13 Therefore, based on the results presented in Figure 1 and Table 1 , we hypothesized that magnolin might differentially inhibit cell-cycle arrest in TOV-112D and SKOV3
ovarian cancer cells. To examine that hypothesis, we initially conducted cell-cycle analysis under normal cell culture conditions.
We observed that magnolin treatment increased the populations of G1
and G2/M phase cells in TOV-112D ovarian cancer cells in a dosedependent manner (Figure 2A , left graph). In contrast, the population Moreover, the phosphorylations of Akt at Thr308, an amino acid directly phosphorylated by PI3 K and PDK1, and Ser473, a target Figure 3B ). However, phospho-RSK at Thr359/Ser363, phospho-RSK2 at S227, and total protein levels of RSKs were higher in SKOV3 cells than in TOV-112D cells ( Figure 3B ). To examine the effects of magnolin on the phosphorylation levels in signaling pathways, we co-stimulated TOV-112D and SKOV3 cells with EGF and magnolin. We found that magnolin suppressed the EGF-induced RSK phosphorylation at Thr359/Ser363 in a dose-dependent manner as similar as a decrease of ERK1/2 phosphorylation ( Figure 3C ).
Interestingly, although phosphorylation of ERK1/2 was very weakly increased by EGF stimulation in SKOV3 cells, the phosphorylation
levels of RSKs at Thr359/Ser363 were also markedly increased by EGF stimulation in SKOV3 cells ( Figure 3C ). Additionally, magnolin minimally reduced the EGF-induced phospho-RSK levels in SKOV3 cells compared to that in TOV-112D cells ( Figure 3C ). Although the increased ratio for phosphorylation of ATF1 at Ser63, which is a target amino acid phosphorylated by RSK2, 18 was similarly increased in both TOV-112D and SKOV3 cells, the SKOV3 cells showed a more marked increase in phopsho-ATF1 levels because of high degree of elevated ATF1 protein levels in SKOV3 cells ( Figure 3D ). Moreover, we confirmed that magnolin suppressed ATF1 phosphorylation only in TOV-112D cells, not in SKOV3 cells, under normal cell culture conditions ( Figure 3E ). Taken together with the results in our previous study, 13 these results demonstrate that molecular targeting of ERK1
and ERK2 with magnolin can suppress ovarian cancer cell lines harboring a general MAPK signaling cascade such as TOV-112D.
These results also suggest that cells containing a bypass signaling pathway of ERK1/2 may induce chemoresistance against therapeutic compounds that target RSK upstream signaling molecules in Ras/Raf/ MEKs/ERKs signaling axis.
| Magnolin induces cellular senescence in TOV-112D, but not in SKOV3
The suppression of cancer cell proliferation induces cellular senescence. 19 Our results demonstrated that magnolin treatment in TOV-
112D ovarian cancer cells inhibits cell proliferation by enhancing
accumulation of cells at the G1 cell-cycle phase ( Figures 1D and 2A) .
Moreover, Ras activation induces the Raf/MEKs/ERKs/RSK2 signaling axis, resulting in increase of cancer cell proliferation. 20 Taken together, these observations suggest that inhibition of cell proliferation by magnolin might induce cellular senescence in TOV-112D cells. To examine that hypothesis, we conducted senescence associated (SA)-β-gal assays using TOV-112D and SKOV3 cells ( Figure 4A ). We observed that magnolin treatment increased SA-β-gal-positive cell population in TOV-112D cells in a dose-dependent manner ( Figure 4A ). In contrast,
we did not observed SA-β-gal-positive SKOV3 cells while the magnolin concentration was increased to 60 µM ( Figure 4A ). The SA-β-galpositive staining of TOV-112D cells was not limited by magnolin, but observed in other ERK inhibitors such as SCH772984 and LY321449
and a MEK inhibitor U0126 ( Figure 4B ). As expected, TOV-112D cells was showed the SA-β-gal-positive cells by specific inhibition of ERKs using SCH772984, but not in SKOV3 (Supplementary Figure S1) . To examine whether magnolin-induced senescence is the cellular senescence or senescence-associated secretory phenotype (SASP),
we firstly examine the transactivation activity of NF-κB, which is an important transcription factor inducing gene expression of SASP related genes. 21 Our results demonstrated that magnolin suppressed NF-κB transactivation activity ( Figure 4C ) as similar as our previous report. 22 In contrast, the inhibition of NF-κB transactivation activity was not observed in SKOV3 cells ( Figure 4C ). Moreover, magnolin did not induce or not alter the expression of IL-6, IL-8, IL-1β, MMP-1, and MMP-3 ( Figure 4D ), which are well known the representative SASP markers. 23 Notably, NF-κB transactivation activity induced by EGF stimulation was suppressed by magnolin treatment ( Figure 4E ).
Importantly, suppressed ERK phosphorylation by transfection of dominant negative of ERK1/2 ( Figure 4F ) induced SA-β-gal-positive cell population ( Figure 4G ). Taken together, inhibition of ERK1/2 by magnolin induces cellular senescence, not SASP, in TOV-112D, resulted in inhibition of TOV-112D proliferation.
| Magnolin suppresses cancer growth of TOV-112D in vivo
A recent study demonstrated that cancer cells harboring cancer stem cell properties resist cellular senescence. 24 To examine whether SKOV3 cells harbor cancer stem cell properties, we undertook sphere ) cells were seeded into 24-well plates, cultured, and treated with indicated doses of magnolin, SCH772984, LY3214996 and U0126 for 24 h. (C) Magnolin suppresses NF-κB transactivation activity. NF-κB-luciferase reporter plasmids were transiently transfected into TOV-112D and SKOV3 cells and cultured for overnight. The cells were treated with indicated doses of magnolin for 12 h and firefly luciferase activities were measured. The equal transfection of NF-κB-luc was compensated using pRL-SV40 Renilla luciferase control plasmids. (D) Magnolin did not alter the gene expression of SASP makers. Total RNA extracted from the magnolin treated TOV-112D and SKOV3 were utilized to measure the gene expression of SASP maker genes by PCR as indicated. The PCR products were visualized by ethidium bromide containing agarose-gel electrophoresis under UV lamp. β-actin was used for the internal control to verify equal experimental condition. (E) Magnolin inhibits EGF-induced NF-κB transactivation activity. NF-κB luciferase reporter plasmids were transfected into TOV-112D cells, starved and treated with EGF or EGF/magnolin for 12 h and firefly luciferase activity was measured. The equal transfection of NF-κB-luc was compensated using pRL-SV40 Renilla luciferase control plasmids. The results demonstrated that SKOV3 cells produced increased
CD44
+ /CD24 − cell populations, which is a typical cancer stem cell marker of ovarian cancer stem cells. 25, 26 In contrast, the CD44 + / CD24 − cell population in TOV-112D cells did not significantly change after sphere formation ( Figure 5A ). Taken together with Figures 2B and   4A and B, we hypothesized that magnolin might suppress TOV-112D
cancer cell growth in athymic nude mice. Unfortunately, there was difficulty obtaining a sufficient quantity of magnolin with a purity level of at least 97% or higher. Thus, we utilized a half purified Shin-Yi fraction 1 in which magnolin was approximately 53% of the total fraction. We implanted TOV-112D cells (6 × 10 6 cells) in the right dorsal flank of athymic nude mice, and when tumor growth reached approximately 100 mm 3 , we randomly divided the mice into two 
| DISCUSSION
Chemoresistance of cancer cells is principally obtained via two different pathways, intrinsic and extrinsic, and such resistance can affect cancer cell survival and stress tolerance. 27 The intrinsic pathway has an important role in drug metabolism in the liver by activating phase I, phase II, and phase III drug metabolizing enzymes. 28 The extrinsic pathway is involved in genetic and epigenetic chemoresistance alterations, resulting in alteration of gene expressions. 27 Generally, genetic alteration of tumor suppressor proteins such as p16, p21, and p53 has a key role in the chemoresistance of various cancer cells. 29 However, signaling studies focused on a specific signaling pathway have not fully elucidated the complicated signaling networks involved in responses to diverse intrinsic and extrinsic stimuli. 30 To assist in that elucidation, the National Cancer and National Human Genome Research Institutes have provided mutaome data obtained from various cancer cells. 31 Those data can provide important clues in researching the relationship between genetic alteration and chemoresistance.
One of the widely reported ways to obtain cancer chemoresistance is to alter the molecular targets of therapeutic agents by modulating gene expression levels or bypassing the target signaling pathway. 32, 33 Although MAPK and PI3 K/Akt signaling pathways are involved in cancer development and chemoresistance, they are generally recognized as two independent but parallel pathways. 33 However, recent interactome studies have indicated that these two signaling pathways influence each other in different signaling transduction processes, both negatively and positively, via multiple cross-talking points. 34 In this study, we observed that ERK1/2 phosphorylation resulting from EGF stimulation in SKOV3 cells was notably weak compared to that in TOV-112D cells ( Figure 3B ).
Interestingly, SKOV3 cells contained high levels of Akt phosphorylation at Thr308 and Ser473, which are critically important to full activation of Akt. Importantly, SKOV3 cells showed very strong responsiveness for RSK phosphorylation at Thr359 and Thr363 (Figure 3B ), which are critically important for RSK activation. 20 The results showing that SKOV3 cells exhibited magnolin resistance during cell proliferation and colony growth in soft agar ( Figure 1D and 2B) suggest that there may be another contact point, one that does not involve ERK1 or ERK2.
Cancer cells harbor the ability to sustain chronic proliferation. In contrast, normal tissues exhibit controlled production and release of growth-promoting signals, ensuring homeostasis of cell numbers for the maintenance of normal tissue function. 35 Thus, elucidation of the mechanisms regulating cell proliferation in normal cells and tissues is important because cancer cells acquire the capability to sustain proliferation via various alternative signaling pathways. 36 Cancer cells may produce auto-growth factor themselves, resulting in autocrine proliferative stimulation. 37 Moreover, loss of regulatory mechanisms controlling cell proliferation can also result from mutation. 38 For example, human melanomas contain about 40% of the activating mutations in B-Raf, resulting in constitutive activation signaling through the Raf to MAPK pathways. 39 Similarly, mutation in the catalytic subunit of PI3 K has been reported in several different human cancers, 40 and the signaling pathway through PI3 K to Akt/mTOR kinase has been reported to coordinate and sustain cancer cell proliferation, growth, and division via regulation of cellular metabolism and homeostasis. 41 Recently, oncogenes such as K-Ras have been shown to mediate cellular and metabolic transformation during tumorigenesis, 42 indicating that MAPK and PI3 K signaling pathways are related to the maintenance of homeostasis in normal and cancer cells. 43 One path to the induction of cancer chemoresistance is the bypassing of cellular senescence, a self-protection mechanism, 44 resulting in immortalization and malignancy. An accumulation of data has indicated that the loss-of-function of tumor suppressors, such as retinoblastoma (RB), p53, and p16, has a critically important role in the process of bypassing cellular senescence. 45, 46 Moreover, the loss of p53 and the tumor suppressor PTEN bypasses cellular senescence to form prostate cancer in mice. 46 Interestingly, mutations in the Rasmediated MAPK family, especially the B-Raf valine-to-glutamate mutation, encourage enhancement of tumorigenesis in melanoma by evasion of p53-dependent senescence. 47 Our current study demonstrated that TOV-112D harbors wildtype p16 and p53 and SKOV3
contains mutant p16 and p53 (Table 1) . Interestingly, magnolin sensitivity on the cell proliferation was obverted in TOV-112D without alteration of SASP markers ( Figure 4D ), indicated that magnolinmediated senescence is cellular senescence that is associated with cell cycle arrest (Figure 2A ). In contrast, we further observed that magnolin induced the protein levels of p16 Ink4a and p27
Kip1
, critical markers for cellular senescence, in xenograft tissues ( Figure 5E ). Unfortunately, we could detect the SA-β-gal activity in tumor tissues because the tissues were fixed in 4% formalin for long period. These results suggest that constitutive active mutation in MAPK and PI3 K signaling pathways have a key role in bypassing cellular senescence.
Recently, genomic analysis of ovarian carcinoma indicated that TP53 mutations are observed about 96% of high-grade serious ovarian cancers. 48 They also found additional somatic mutations in genes, including NF1, BRACA1, BRCA2, RB1, and CDK12, with low prevalence but statistically recurrence. 48 The somatic mutations of BRCA1 and 2 are associated with other genes that are involved in DNA repair in high-grade ovarian cancers. 48 However, high-grade ovarian cancer are associated with about 10-20% germline mutations in BRCA1 and 2, 49 indicated that tumor suppressors plays a key role in ovarian cancer development. Moreover, it is clear that constitutive active mutations in MAPK signaling pathway was observed about each 11% of total epithelial ovarian cancers in B-Raf and K-Ras genes, respectively. 50 On the other hand, constitutive active mutation of PI3 K (PI3KCA) and loss-of-function of PTEN was observed with about 6.7 and 20% of the total epithelial ovarian cancers. 50, 51 Analysis of the CCLE mutaome data has indicated that SKOV3 cells contain a constitutively active mutation in PI3 K and loss-of-function mutations in p16 and p53 (Table 1) . Moreover, SKOV3 cell showed negative results following SA-β-gal staining and magnolin treatment, whereas, the opposite results were obtained with TOV-112D cells ( Figure 4A ).
Importantly, we observed that the ovarian cancer cell marker CD44 + / CD24 − was enriched in sphere-formed SKOV3 cells, but not in sphere- 
